TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, Feb. 14 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Company") (TSX Venture Exchange: AVI) announces today that a second
preclinical study conducted by Dr Charles Doillon, M.D, PhD from the Oncology
and Molecular Endocrinology department of the Centre de Recherche du Centre
Hospitalier de l'Université Laval ("CHUL") has provided new indications of the
wound healing properties of a milk devired fraction originating from the
research work on its XP828L and IM technological platforms.
New data reveals that Advitech's fraction is capable of enhancing
biochemical activity of fibroblasts (relative to cell proliferation and
collagen synthesis) while preventing physiological phenomena that can result
in excessive scaring. This further confirms that this fraction, when used
under specific conditions, acts early in the repair process by increasing the
number of fibroblasts present in the wound, resulting in the production and
deposition of collagen fibres present in the newly formed wound tissue. In
addition, the fraction appears to modulate excessive remodelling of collagen
fibres during the late phase of the wound repair process.
"This feature would constitute a major advantage in plastic and
reconstructive surgery wherein the intention is to limit the amount of
scaring. In addition, there appears to be utility for natural products like
the fraction generated by Advitech's platform for these applications" noted
Christina Juneau PhD, vice-president R&D at Advitech added, "We now have
a more comprehensive R&D program on wound healing and repair in place, which
should enable the development of specific fractions that can be used in
pharmaceutical applications. We expect to announce new data and results in the
second quarter of 2008".
"Since the first announcement on the positive wound healing application
results in October 2007, this has opened new market opportunities for
Advitech. The positive results generated by our preclinical program have led
us to consider new priorities in our business strategy to capitalize on
opportunities created by the wound healing platform. We anticipate issuing an
update in our business review in the coming weeks." commented
Renaud Beauchesne, president and chief executive officer.
About Wound Healing:
According to Espicom Business Intelligence Ltd., the global wound care
market totalled $7.2 billion in 2006, with a 10% growth rate. Growth factor
based applications for wound-healing represent more than 5% of the market,
with an impressive 27% growth rate.
About Advitech Inc. www.advitech.com:
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
Advitech has drawn up a research program to develop new applications
related to wound healing. This development is derived from both its XP-828L
and IM technological platforms.
About Dermylex(R) www.dermylex.com:
Dermylex(R), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, including a 112-day, multi-center, double-blind, placebo-controlled
trial with 84 patients, clinically proved the efficacy and safety of
Dermylex(R) for that type of psoriasis. Dermylex(R) is currently available in
Canada and the U.S. (as BioDerm, Dermalyx(R)), as well as in France and
Belgium (as Psopax(R)).
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,
email@example.com; Serge Comeau, Investor's relations, (514) 862-4160,